The NF-κB (Nuclear Factor Kappa B) signaling pathway is a central regulator of neuroinflammation and cell survival in neurodegenerative diseases. While acute NF-κB activation is protective, chronic activation drives progressive neuroinflammation, synaptic dysfunction, and neuronal loss in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and related disorders[1]. NF-κB represents one of the most thoroughly studied yet therapeutically challenging targets in neurodegeneration research.
For comprehensive coverage including molecular mechanisms, therapeutic approaches, and detailed references, see NF-κB Signaling in Neurodegeneration.
The NF-κB family consists of five closely related transcription factors that form various homo- and heterodimers:
| Member | Alternative Name | Dimer Partners | Key Roles |
|---|---|---|---|
| p65 (RelA) | RELA | p50, c-Rel, RelB | Pro-inflammatory gene activation |
| p50 | NFKB1 | p65, c-Rel | DNA binding, repression |
| c-Rel | REL | p50, p65 | Lymphoid development, survival |
| RelB | RELB | p52 | Non-canonical signaling |
| p52 | NFKB2 | RelB, p65 | Non-canonical pathway |
The most common dimers in the nervous system are p65/p50 (canonical) and RelB/p52 (non-canonical)[@kalinina2006].
The IκB kinase (IKK) complex serves as the master regulator of canonical NF-κB signaling. The complex comprises:
IKKβ phosphorylation of IκBα at Ser32 and Ser36 triggers its polyubiquitination and proteasomal degradation, liberating NF-κB dimers for nuclear translocation[@kiss2011].
The canonical NF-κB pathway is activated by diverse pro-inflammatory stimuli including cytokines (TNF-α, IL-1β), pathogen-associated molecular patterns (LPS), and disease-specific ligands such as Aβ oligomers and α-synuclein aggregates[2]. Receptor engagement triggers recruitment of adaptor proteins that ultimately activate the IKK complex. Activated IKK phosphorylates IκBα, targeting it for ubiquitination and proteasomal degradation. Freed p65/p50 dimers translocate to the nucleus where they bind specific κB DNA sequences and recruit coactivators (CBP/p300) to drive transcription of inflammatory, survival, and synaptic genes[@kaltschmidt2007].
The non-canonical NF-κB pathway operates through a distinct mechanism controlled by NIK (NF-κB-inducing kinase) and proteolytic processing of p100[3]:
This pathway is critical for adaptive immune responses and is implicated in CNS autoimmunity and chronic neuroinflammation. In neurodegeneration, non-canonical signaling contributes to microglial polarization and T-cell infiltration across the blood-brain barrier.
The canonical NF-κB pathway is activated by pro-inflammatory cytokines (TNF-α, IL-1β), pathogen-associated molecular patterns (LPS), and cellular stress[@kiss2011]:
The alternative pathway uses NF-κB inducing kinase (NIK) to process p100 to p52, generating RelB/p52 dimers with distinct gene targets[3:1].
NF-κB is one of the earliest and most consistent findings in AD[4]:
NF-κB contributes to dopaminergic neuron loss[5]:
NF-κB drives motor neuron degeneration[6]:
NF-κB activation in brain endothelial cells contributes to BBB breakdown across neurodegenerative conditions. Pro-inflammatory cytokines activate NF-κB in endothelial cells, increasing expression of adhesion molecules (VCAM-1, ICAM-1) and chemokines that facilitate leukocyte transmigration. This is particularly relevant in MS, AD, and traumatic brain injury[@eissner2022].
ER stress and NF-κB are interconnected through multiple mechanisms[7]. The IRE1α branch of the unfolded protein response activates NF-κB via IKK, while PERK-eIF2α signaling cross-talks with the NF-κB pathway. In neurodegenerative conditions with significant protein misfolding (AD, PD, ALS), ER stress-mediated NF-κB activation drives chronic neuroinflammation.
| Approach | Examples | Status | Notes |
|---|---|---|---|
| IKK inhibitors | MLN120B, BAY 11-7082 | Preclinical | Broad immunosuppression |
| IκB stabilization | Bortezomib | Preclinical | Proteasome inhibitor |
| Natural products | Curcumin, Resveratrol | Clinical trials | Poor bioavailability |
| Cell-type delivery | Nanoparticles, viral vectors | Preclinical | Targeted approaches |
| Gene therapy | NF-κB decoys, siRNA | Preclinical | Experimental |
| Decoy oligos | NF-κB decoy nucleotides | Phase 2 | Topical/local delivery |
| TAK1 inhibitors | RK-33 | Preclinical | Dampens both pathways |
Emerging approaches aim to selectively modulate NF-κB in disease-relevant cell types:
NF-κB intersects with multiple neurodegeneration-relevant pathways:
NF-κB signaling sits at the intersection of neuroinflammation and neurodegeneration. The pathway's dual nature—both protective and pathogenic—creates a therapeutic paradox. Successful approaches will require cell-type-selective modulation, timing based on disease stage, and probably combination therapies. See the comprehensive page for detailed molecular mechanisms, therapeutic strategies, and complete references.
Shih RH, Wang CY, Yang CM. "NF-κB signaling pathways in neurological disorders". 2015. ↩︎
Mattson MP, Meffert MK. "Roles for NF-κB in the biological functions of neural cells". 2005. ↩︎
Sun SC. "The noncanonical NF-κB pathway". 2012. ↩︎ ↩︎
Chen CH, Zhou W, Qu J, Singh K, Hayes C, Lee LM, et al. "NF-κB as a therapeutic target in Alzheimer's disease". 2012. ↩︎
Ghosh A, Mondal S, Rajamma U. "NF-κB in Parkinson's disease: a novel therapeutic target". 2017. ↩︎
Dresselhaus D, Meffre MK. "NF-κB in amyotrophic lateral sclerosis: therapeutic potential". 2020. ↩︎
Ho YS, Yang X, Lau JC, Hung CL, Wuwongse S, Zhang Q, et al. "Endoplasmic reticulum dysfunction in neurodegenerative disease". 2016. ↩︎